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Several members of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) family have been identified as
aggrecanases, whose substrates include versican, the principal large proteoglycan in the tendon extracellular matrix. We have characterized the
expression of ADAMTS-4 in human Achilles tendon and tendon-derived cells. ADAMTS-4 mRNA levels were higher in ruptured tendon compared
with normal tendon or chronic painful tendinopathy. In tissue extracts probed byWestern blotting, mature ADAMTS-4 (68 kDa) was detected only in
ruptured tendons, while processedADAMTS-4 (53 kDa) was detected also in chronic painful tendinopathy and in normal tendon. In cultured Achilles
tendon cells, transforming growth factor-β (TGF-β) stimulated ADAMTS-4 mRNA expression (typically 20-fold after 24 h), while interleukin-1
induced a smaller, shorter-term stimulation which synergised markedly with that induced by TGF-β. Increased levels of immunoreactive proteins
consistent with mature and processed forms of ADAMTS-4 were detected in TGF-β-stimulated cells. ADAMTS-4 mRNAwas expressed at higher
levels by tendon cells in collagen gels than in monolayer cultures. In contrast, the expression of ADAMTS-1 and -5mRNAwas lower in collagen gels
compared with monolayers, and these mRNA showed smaller or opposite responses to growth factors and cytokines compared with that of
ADAMTS-4 mRNA. We conclude that both ADAMTS-4 mRNA and ADAMTS-4 protein processing may be differentially regulated in normal and
damaged tendons and that both the matrix environment and growth factors such as TGF-β are potentially important factors controlling ADAMTS
aggrecanase activities in tendon pathology.
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Tendons such as theAchilles are susceptible to chronic painful
degenerative tendinopathy (Åström and Rausing, 1995) andAbbreviations: ADAMTS, A Disintegrin And Metalloproteinase with
ThromboSpondin motifs; Ct, threshold cycle; DMEM, Dulbecco's modified
Eagle's medium; EGF, epidermal growth factor; FCS, fetal calf serum; FGF,
fibroblast growth factor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
IL-1β, interleukin-1β; PDGF, platelet-derived growth factor; TGF-β, trans-
forming growth factor-β; TNF, tumour necrosis factor.
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doi:10.1016/j.matbio.2008.02.002‘spontaneous’ ruptures in the absence of previous symptoms
(Waterston et al., 1997). A combination of histological, bio-
chemical and molecular biological studies have indicated that
there is a normal balance between the synthesis and degradation
of tendon matrix components, which is disrupted in chronic or
acute tendon damage (Kannus and Jozsa, 1991; Jarvinen et al.,
1997; Movin et al., 1997; Maffulli et al., 2000; Riley et al., 1994,
2002; Riley, 2004). For example, there aremultiple differences in
gene expression in degenerate Achilles tendons compared to
normal tendons, including the expression of extracellular matrix
components and the enzymes that degrade them (Ireland et al.,
2001; Corps et al., 2006; Jones et al., 2006).
Subfamily M12B of the metalloproteinases (http://merops.
sanger.ac.uk/) comprises the ADAM (A Disintegrin Andix Biology. All rights reserved.
Fig. 2. ADAMTS-4 immunoreactivity in tendon tissue. Western blots of protein
extracts (10 μg/lane) from 3 samples each of normal, painful and ruptured tendon
tissue were probed using the ADAMTS-4-specific antibodies (A) AHP821GA
and (B) PA1-1749. The lane marked cell contained extract from a TGF-β-treated
tendon cell culture. The arrows indicate the mature and processed forms of the
ADAMTS proteins discussed in the text. Similar results were obtained using 3
further samples per tissue group, run on a separate pair of blots.
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proteinase with ThromboSpondin motifs) enzymes. ADAMTS-1,
-4 and -5 have been characterised as aggrecanases which cleave
aggrecan at specific sites (Caterson et al., 2000; Kuno et al., 2000;
Tang, 2001; Tortorella et al., 2001). ADAMTS-1 and -4 have also
been shown to cleave versican (Sandy et al., 2001; Westling et al.,
2004), which is the principal large proteoglycan expressed in mid-
tendon (Robbins and Vogel, 1994; Benjamin and Ralphs, 1998;
Waggett et al., 1998). In addition, ADAMTS-8, -9 and -15 have
been reported to cleave aggrecan (Somerville et al., 2003; Collins-
Racie et al., 2004). Cleavage products consistent with ADAMTS-
specific activity are observed in cartilage and synovium explant
systems and in vivo (Ilic et al., 1992; Caterson et al., 2000; Sandy
et al., 2001; Tortorella et al., 2001; Vankemmelbeke et al., 2001;
Patwari et al., 2005) and in bovine flexor tendons (Rees et al.,
2000; Samiric et al., 2004), but no data have been reported for
human tendons.
Using relative quantitative RT-PCR, we recently screened
RNA samples from normal Achilles tendons and from
individuals suffering either chronic tendon pain or spontaneous
tendon rupture, for mRNA encoding all the known matrix
metalloproteinases, ADAMTS and tissue inhibitors of metallo-
proteinases (TIMP) (Jones et al., 2006). In that screen, mRNA
encoding the aggrecanases ADAMTS-1, -4, -5, -8, -9 and -15
were each detected. Of these mRNA, ADAMTS-1 mRNAwas
expressed at highest levels but showed little difference between
normal, painful and ruptured tendons, while ADAMTS-
4 mRNA showed the largest change, increasing 8-fold in
ruptured tendons (Jones et al., 2006). Previous studies have
highlighted the potential role of growth factors such as platelet-
derived growth factor (PDGF) and transforming growth factor-β
(TGF-β) in tendon pathology (Fenwick et al., 2001; Rolf et al.,
2001), but little is known about their effect on aggrecanases. In
addition, the mechanical environment acting on tenocytes
cultured in a three-dimensional matrix has been shown to
regulate some metalloproteinase activities (Lavagnino and
Arnoczky, 2005). We have now tested the effects of growth
factors on the regulation of ADAMTS-4 mRNA expression in
Achilles tendon-derived cells in both monolayer and three-Fig. 1. ADAMTS-4 mRNA expression in normal, painful and ruptured tendon.
Tendon RNA samples were analysed for ADAMTS-4 mRNA, expressed
relative to 18S rRNA as outlined in the text. Each point represents an individual
sample. The median values are shown (horizontal bar). ** Pb0.01, † Pb0.05,
for differences between ruptured tendon and the normal and painful tendon
groups respectively, by Wilcoxon rank sum test.dimensional collagen gel cultures, and examined the expression
of ADAMTS-4 protein in tendon tissues and cells.
2. Results
2.1. Expression of ADAMTS-4 mRNA and protein in tendon
tissue samples
We first confirmed the results of our previous screen of tendon
tissue RNA (Jones et al., 2006), using an extended sample set
(n=14 per group) and a second, independently-derived, relative
quantitative real-time RT-PCR primer-probe set, which was also
used to determine ADAMTS-4 mRNA expression in the cell
studies described below. ADAMTS-4 mRNA expression was
detected in all tendon tissue samples. Normal, painful and
ruptured tendon samples showed median values of ADAMTS-
4 mRNA expression, relative to 18S rRNA, of 0.29×10−6,
0.45×10−6 and 3.07×10−6 respectively (Fig. 1). The ruptured
group differed significantly from the normal and painful groups
(Pb0.01 and Pb0.05, respectively, by Wilcoxon rank sum test).
To assess the levels and processing of ADAMTS-4 protein in
tendon tissue, we extracted samples using a neutral extraction
buffer containing NP-40 (Gao et al., 2002). The major band
detected by antibody AHP821GA (raised against a C-terminal
domain peptide) was consistent with the mature 68 kDa form of
ADAMTS-4 (Fig. 2A), while the major band detected by
antibody PA1-1749 (raised against a catalytic domain peptide)
was consistent with the processed 53 kDa form of ADAMTS-4
(Fig. 2B). The 68 kDa form of ADAMTS-4 was detected
Fig. 3. Regulation of ADAMTS-4 mRNA expression in cultured tendon cells by
growth factors and cytokines. Tendon cells were incubated for 6, 24 or 48 h with
EGF (10 ng/ml,■), FGF (1 ng/ml, ▲), PDGF (10 ng/ml,●), TNF (10 ng/ml, ♦),
IL-1β (1 ng/ml, □), TGF-β (1 ng/ml, Δ) or TGF-β plus IL-1β (panel C, filled
column). Total cell RNA was extracted and analysed for ADAMTS-4 mRNA,
expressed relative to GAPDH mRNA and normalised to the value obtained for
control cells at the same time-point (defined as 100% and shown as a broken line).
Results aremean±s.e.m. from at least 4 experimentswith each agonist (panelsA,B)
or 3 experiments (panel C); *Pb0.05, **Pb0.01 compared with the control at the
same time point, determined from 95% or 99% confidence intervals of the treated
samples; † Pb0.05 for TGF-β plus IL-1β compared with either cytokine alone.
Fig. 4. Regulation of ADAMTS-4 mRNA expression in cultured tendon cells by
TGF-β and BMP. Tendon cells were incubated for 24 h with TGF-β or BMP-2,
-7 or -13 at the concentrations shown (ng/ml). Total cell RNAwas extracted and
analysed for ADAMTS-4 mRNA, expressed relative to GAPDH mRNA and
normalised to the mean value obtained for control cells (defined as 100%).
Results shown are mean±s.e.m. of three wells per treatment in a single
experiment; * Pb0.05, *** Pb0.001 by t-test. Similar results were obtained in
a separate experiment with cells derived from a second donor.
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in normal or painful tendon samples (Fig. 2A and data not
shown). The 53 kDa form was detected in only three of the six
samples of normal tendon tested, and to a variable extent in
ruptured tendon samples, but was readily detected in all samplesof painful tendon (Fig. 2B and data not shown). The detection of
the two principal forms of ADAMTS-4 by these two antibodies
was also observed in samples of cultured cells extracted using
the NP-40-containing buffer (Fig. 2, lane marked cell).
The preference of the PA1-1749 antibody for the 53 kDa form
of ADAMTS-4 (Fig. 2B) is in agreement with studies using
cartilage extracts (Gao et al., 2002; Patwari et al., 2005). Several
additional faint bands were present across all lanes and may
represent non-specific cross-reactivity (Fig. 2B); of these, a band
of about 70 kDa prevented the unequivocal detection of the
68 kDa form of ADAMTS-4 by this antibody. The preference of
the C-terminal domain antibodyAHP821GA for the 68 kDa form
of ADAMTS-4 (Fig. 2A) is similar to that of an antibody raised
against the cysteine-rich region of ADAMTS-4 used by Patwari
et al. (2005), although the precise epitope of AHP821GAwithin
the cysteine-rich and spacer regions was not defined by the
supplier. An additional band of between 55 and 60 kDa was
detected by the antibody AHP821GA, principally in those
samples with high expression of the 68 kDa form (Fig. 2A); this
may represent an additional or alternative cleavage of the 68 kDa
form in the spacer domain.
2.2. Regulation of ADAMTS-4 mRNA expression in cultured
tendon cells
Tendon cells in culture expressed each of ADAMTS-4,
ADAMTS-1 and ADAMTS-5 mRNA. When the cells were
rinsed into fresh serum-free medium, ADAMTS-4 mRNA levels
in control cells showed a decrease during the first 48 h incubation,
but subsequently showed only small (less than 2-fold) variations
that were not consistent between experiments (data not shown).
Growth factors and cytokines, added to the cells after 48 h
adaptation to serum-free medium, stimulated the expression of
ADAMTS-4 mRNA, with different characteristic time-course
and magnitude (Figs. 3 and 4). Epidermal growth factor (EGF),
fibroblast growth factor (FGF) or PDGF each induced small
transient stimulations of ADAMTS-4mRNA levels (about 3-fold
Fig. 5. ADAMTS-4 protein expression in cultured tendon cells. Western blots of
protein extracts from tendon cell cultures incubated for 24 h with vehicle (Con)
or TGF-β (1 ng/ml) were probed using the ADAMTS-4-specific antibodies (A)
AHP821GA and (B) PA1-1749. The arrows indicate the mature (68 kDa) and
processed (53 kDa) forms of ADAMTS-4 discussed in the text. Similar results
were obtained in two additional experiments.
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similar time-course but was greater in magnitude, reaching more
than 10-fold (Fig. 3B), while stimulation by tumour necrosis
factor (TNF) showed a significantly longer time-course, increas-
ing between 6 and 24 h to 8-fold (Fig. 3A).
The greatest stimulation of ADAMTS-4mRNA expression by
an individual growth factor or cytokine was induced by TGF-β
(Figs. 3 and 4). Detectable stimulation was obtained using 0.1 ng/
ml TGF-β and maximum stimulation (typically more than 20-Fig. 6. Regulation of ADAMTS-1 and ADAMTS-5 mRNA expression in cultured te
total cell RNAwas analysed for ADAMTS-1 or ADAMTS-5 mRNA, as described in
each agonist; * Pb0.05, ** Pb0.01 compared with the control at the same time poinfold) occurred after 24 hwith 1–10 ng/ml TGF-β. The stimulation
of ADAMTS-4mRNAbyTGF-β showed amarked synergywith
that induced by IL-1β (Fig. 3C); the combination of TGF-β with
IL-1β induced substantially higher levels of ADAMTS-4 mRNA
over the early period when IL-1β was active individually (6–
12 h), but by 24 h the combined stimulation was not reproducibly
different from that achieved using TGF-β alone (Fig. 3C). Other
members of the TGF-β superfamily, the bone morphogenetic
proteins (BMP), have been implicated in tendon damage and
repair (Aspenberg and Forslund, 2000; Neuwirth et al., 2006).We
therefore tested BMP-2, BMP-7 and BMP-13 for effects on
tendon cell mRNA expression. None of these BMP stimulated
ADAMTS-4 mRNA expression, compared with 10- to 30-fold
stimulation by TGF-β (Fig. 4). However, both BMP-2 and BMP-
13 stimulated the expression of aggrecan mRNA between 4- and
14-fold in the same cell samples (data not shown), indicating that
active receptor signalling occurred over the dose range used.
2.3. Expression of ADAMTS-4 protein in tendon cells
Tendon cell protein extracts, prepared by lysis in the sameNP-
40-containing extraction buffer used for tendon tissue samples,
contained ADAMTS-4-immunoreactive bands consistent with
themature (68 kDa) and processed (53 kDa) forms of the enzymendon cells. Tendon cells were incubated with growth factors and cytokines, and
the legend to Fig. 3. Results are mean±s.e.m. from at least 4 experiments with
t, determined from the 95% or 99% confidence intervals of the treated samples.
Fig. 7. Regulation of ADAMTS-4 mRNA expression in tendon cells cultured in
collagen gels. Tendon cells in monolayer cultures (open columns) or collagen
gels (filled columns)were incubated for 24 hwith vehicle (Con), IL-1β (1 ng/ml),
TGF-β (1 ng/ml) or TNF (10 ng/ml). Total cell RNAwas extracted and analysed
for ADAMTS-4 mRNA, expressed relative to 18S rRNA and normalised to the
value obtained for control cells in monolayer culture or gel respectively (defined
as 100%): note that the mean control level in collagen gels was 2.6-fold higher
than that in monolayer cultures. Results shown are mean±s.e.m. from 4
experiments; * Pb0.05, ** Pb0.01 compared with the respective control values,
determined from the 95% or 99% confidence intervals of the treated samples.
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intensity in cells treated for 24 h with TGF-β (Fig. 5). In some
experiments, the increase could be detected at 6 or 12 h, but by
48 h there was no reproducible difference in the intensity with/
without TGF-β (data not shown). In contrast to TGF-β, IL-1β
did not reproducibly increase the levels of ADAMTS-4 proteins
in cell extracts at 6–12 h (data not shown), i.e. at the time when
IL-1β stimulated ADAMTS-4 mRNA (Fig. 3B). This may be
related to the lower level of mRNA stimulated by IL-1β than by
TGF-β (Fig. 3B), but it is also possible that IL-1β may also
stimulate ADAMTS-4 protein turnover; it has been reported that
IL-1 can alter ADAMTS-4 processing in cartilage explants
(Patwari et al., 2005; see also Discussion).
2.4. Comparison of cellular ADAMTS-1 and ADAMTS-5 mRNA
expression with that of ADAMTS-4 mRNA
We noted previously (Jones et al., 2006) that ADAMTS-
1 mRNA expression showed little variation between tendon tissue
sample groups while ADAMTS-5 mRNA decreased in painful
tendons, thus contrasting with the pattern of ADAMTS-4 mRNA
expression. In the present study, growth factors and cytokines had
differential effects on ADAMTS-1 or ADAMTS-5 mRNA
expression (Fig. 6) compared with that of ADAMTS-4 (Fig. 3).
None of EGF, FGF and PDGF had a significant effect on
ADAMTS-1 mRNA expression (Fig. 6A), but each induced sig-
nificant decreases in ADAMTS-5 mRNA levels (Pb0.01, except
for PDGF Pb0.05), which were maintained over 48 h (Fig. 6C).
The addition of TNF or IL-1β induced a transient decrease
of ADAMTS-1 mRNA expression: a significant decrease at 6 h
(64±4% by TNF, 55±5% by IL-1β), was followed by a return to
control levels or higher at 24 h (Fig. 6A,B). Similarly, TNF and IL-
1β induced a transient decrease of ADAMTS-1 mRNA expres-
sion (Fig. 6C,D). Finally, TGF-β had contrasting effects on these
twomRNA, inducing a small (2- to 3-fold) transient stimulation of
ADAMTS-1 mRNA expression at 24 h (Fig. 6B) and a persistent
decrease of ADAMTS-5 mRNA (Fig. 6D).
2.5. Cellular ADAMTS mRNA expression in three-dimensional
collagen gel cultures
When cells were placed in three-dimensional collagen gel
cultures, ADAMTS-4 mRNA levels increased compared with
those in parallel monolayer cultures (Table 1). In further con-Table 1
Expression of ADAMTS mRNA in tendon cells incubated for 48 h in collagen
gels relative to parallel monolayer cultures
mRNA (Gel/monolayer×100%)
ADAMTS-4 494±144 (Pb0.05)
ADAMTS-1 27±13 (Pb0.01)
ADAMTS-5 34±14 (Pb0.01)
GAPDH 94±28 (ns)
ADAMTS or GAPDH mRNAwas normalised to 18S rRNA, and the value for
collagen cultures was expressed relative to that in parallel monolayer cultures of
the same cells (defined as 100%). Mean±s.e.m. from experiments using cells
from 5 separate patients. P values were determined from a one-sample t-test
against a theoretical mean of 100%. ns=not significant.trast with ADAMTS-4, levels of both ADAMTS-1 and
ADAMTS-5 mRNAwere lower in cells in collagen gel cultures
compared with monolayers (Table 1). These differences were
established over the first 48 h of serum-free culture in collagen
gel or monolayer (Table 1) and then persisted for up to 7 days
without significant change (data not shown). Each of IL-1β,
TGF-β and TNF were able to stimulate ADAMTS-4 mRNA
expression above the raised basal level in collagen gels (Fig. 7),
indicating that there was no general mechanistic interference
between the cytokine-induced and gel-induced stimuli.
3. Discussion
Various studies have indicated that there is a balance between
the synthesis and breakdown of matrix components in normal
tendons, and that this balance is disrupted in tendinopathies (see
Introduction). In this paper we have shown that mRNA
encoding the aggrecanase ADAMTS-4 is regulated indepen-
dently from ADAMTS-1 or ADAMTS-5 mRNA in both human
Achilles tendon tissue samples and cultured tendon cells, and
that mature and processed forms of ADAMTS-4 protein may be
detected in tendon tissue and cellular extracts.
Independent regulation of the ADAMTS aggrecanase genes
has been noted in several tissues (Flannery et al., 2000; Bau et al.,
2002; Pratta et al., 2003; Kevorkian et al., 2004; Moulharat et al.,
2004; Wachsmuth et al., 2004; Cross et al., 2005). Our studies
indicate that both the biomechanical environment and various
cytokines and growth factors can contribute differential regula-
tory effects to ADAMTS gene expression in tendon cells. Each of
EGF, FGF and PDGF increased ADAMTS-4 and decreased
ADAMTS-5 mRNA expression respectively, which is the first
demonstration of such effects of these growth factors. Several
previous studies have described effects of IL-1β on ADAMTS
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considerable variation in the degree of stimulation observed
(Caterson et al., 2000; Tortorella et al., 2001; Vankemmelbeke
et al., 2001; Koshy et al., 2002; Yaminishi et al., 2002; Tzusaki
et al., 2003; Wachsmuth et al., 2004; Patwari et al., 2005). The
only previous study using human tendon cells reported small,
variable, effects of IL-1β on ADAMTS-4 mRNA expression,
measured after 16 h (Tzusaki et al., 2003): our work indicates that
the optimum stimulation by IL-1β occurs at an earlier time (6 h—
Fig. 3). In contrast, there was a marked transient decrease in
ADAMTS-1 and ADAMTS-5 mRNA expression after this time
of treatment with either IL-1β or TNF (Fig. 6).
TGF-β induced the largest stimulation ofADAMTS-4mRNA
expression by any individual growth factor, and co-addition of
TGF-βwith IL-1β gave a marked synergy (Fig. 3), which has not
been described previously. TGF-β also induced a small
stimulation of ADAMTS-1 mRNA expression but decreased
that of ADAMTS-5 (Fig. 6). Contrasting effects of TGF-β on
different ADAMTS mRNA have been reported previously in
synoviocytes (Yaminishi et al., 2002), chondrocytes (Moulharat
et al., 2004) and prostate stromal cells (Cross et al., 2005). We
also tested several BMP, members of the TGF-β superfamily
which have been implicated in tendon damage and repair
(Aspenberg and Forslund, 2000; Neuwirth et al., 2006) and
which act through related receptors to activate different SMAD
transcription factors from TGF-β (Shi and Massague, 2003).
However, none of these BMPhad effects similar to those of TGF-
β onADAMTS-4mRNA (Fig. 4). The activation of ADAMTS-4
expression thus shows a degree of specificity within the TGF-β
superfamily-SMAD signalling network.
In fetal bovine tendon, TGF-β has been implicated in
mediating the effects of compressive loading on matrix gene
expression (Robbins et al., 1997). Indeed, mechanical loading of
tendon is a potential regulatory mechanism for metalloprotei-
nase gene expression (Banes et al., 1999; Lavagnino et al., 2003;
Lee et al., 2005) that might complement the regulation of
ADAMTS expression by growth factors and cytokines.
Mechanotransduction signals are mediated, at least in part, by
interactions of cells with the three-dimensional environment of
the extracellular matrix (Garvin et al., 2003; Lavagnino and
Arnoczky, 2005). We found that placing tendon cells in a three-
dimensional collagen gel (a version of the fibroblast-populated
collagen lattice: Ehrlich and Rittenberg, 2000; Grinnell, 2003)
increased the expression of ADAMTS-4 mRNA relative to the
monolayer and decreased that of ADAMTS-1 and ADAMTS-5
(Table 1). At least three factors may contribute to these effects (i)
a specific interaction of the cells with collagen, (ii) a response to
being in three dimensions rather than two, and (iii) a response to
tension within the matrix. Although further work will be
required to distinguish between these and other explanations, in
initial experiments we have found no reproducible difference in
ADAMTS expression between cells in anchored collagen gels
(as in Table 1) and parallel gels that were free-floating, having
been released from the culture dish (data not shown).
Studies using explant and cell cultures from other tissues have
shown increased aggrecanase activity under conditions where
ADAMTS mRNA and/or protein levels are not altered (Catersonet al., 2000; Flannery et al., 2000; Yaminishi et al., 2002; Pratta
et al., 2003; Patwari et al., 2005), indicating that both the trans-
lation of the mRNA and the processing of the ADAMTS pro-
enzymes are subject to regulation. In tendon tissue extracts, we
found that mature 68 kDa ADAMTS-4 immunoreactivity was
principally detected in ruptured tendons, consistent with the
elevation of mRNA in these samples (Figs. 1 and 2). However, in
each clinical group, notably in painful tendinopathy, there were
significant levels of the 53 kDa form detected preferentially by the
PA1-1749 antibody (Fig. 2B). These results suggest that altered
processing of ADAMTS-4 protein may occur between the dif-
ferent clinical groups. The principal change observed in the cel-
lular expression of ADAMTS-4 protein in vitro was an increased
level (of both main ADAMTS-4 forms) in cells stimulated by
TGF-β (Fig. 5). In some experiments, we observed a band of 40–
45 kDa (reactive with the PA1-1749 antibody) in TCA-pre-
cipitated supernatant medium from 48-h -incubated cells (data not
shown). This band was significantly smaller than the 53 kDa band
present in cell extracts, and was elevated in cultures treated with
either TGF-β or IL-1β. It may thus represent further processing
and release of ADAMTS-4 from the cells in response to these
cytokines, analogous to some of the effects reported in othermodel
systems (Patwari et al., 2005).
In conclusion, we have shown that ADAMTS-4 mRNA is
regulated differentially from ADAMTS-1 and ADAMTS-
5 mRNA in Achilles tendon and tendon-derived cells in vitro,
and that active forms of ADAMTS-4 are present in the tendon
tissues. The apparent functional redundancy of the ADAMTS
aggrecanases is complex, as emphasised in studies of gene knock-
outs in mice, which indicate a major role for ADAMTS-5 aggre-
canase inmouse cartilage (Stanton et al., 2005), but notADAMTS-
1 or ADAMTS-4, despite the fact that these are expressed in this
tissue (Glasson et al., 2004; Little et al., 2005). However, none of
these gene knockout studies addressed the question of ADAMTS
aggrecanase function in tendon. Further studies will be required to
determine the contribution ofADAMTS-4 to the observed changes
in proteoglycans in tendinopathy.
4. Experimental procedures
4.1. Materials
Dulbecco's modified Eagle's medium (DMEM), fetal calf
serum (FCS), antibiotics and oligonucleotide primers were
obtained from Invitrogen (Paisley, UK). One-Step RT-PCR
reagents and FAM-labelled oligonucleotide probes were
obtained from Applied Biosystems (Warrington, UK) and
Sigma-Genosys (Haverhill, UK). IL-1β was a gift from Glaxo
Wellcome (Stevenage, UK) and aliquots (1 μg/ml) were stored at
−70 °C. Other growth factors and cytokines were obtained from
R&D Systems (Abingdon, Oxford, UK) or Insight Biotechnol-
ogy (Wembley, UK) and were solubilised and stored according
to the suppliers' instructions. Primary anti-ADAMTS-4 anti-
bodies were as follows: antibody AHP821GA, raised against a
C-terminal domain peptide, was from Serotec (Oxford, UK);
antibody PA1-1749, raised against a catalytic domain peptide
(also referred to as JSCVMA: Patwari et al., 2005) was from
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Cambridge Bioscience (Cambridge, UK). Horseradish perox-
idase-coupled secondary antibodies were from Dako (Ely, UK).
4.2. Tendon specimens
All procedures had appropriate local ethical committee
approval, and consent was obtained from informed patients. A
detailed characterisation of the sample groups has been published
(Jones et al., 2006). Normal Achilles tendon specimens were
obtained from cadaver material, taken within 48 h of death, or
from patients undergoing amputation of the leg for the removal of
bone tumours, and showed normal histological appearance.
Tissue from individuals suffering painful tendinopathy for more
than 6monthswas taken from the site of the lesion during surgery
and showed abnormal histological appearance. Tissue from
individuals undergoing repair of ruptured tendon, mostly within
48 h of the rupture occurring, was trimmed from the site of the
rupture. Specimens were transported to the laboratory in ice-cold
balanced salts solution, and were stored frozen at −70 °C. The
age of the individuals (14 per group) from which tissue was used
for RNA analysis was as follows: normal tendon, range 20–
97 years, median 55; painful tendinopathy, range 32–59 years,
median 43; ruptured tendon, range 25–69 years, median 45.
None of the ADAMTS mRNA expression showed a significant
variation with age in this study (data not shown).
4.3. RNA isolation from tendon tissue samples
Total RNA was isolated from frozen tissue samples by a
modified Tri-Spin protocol as described previously (Ireland
et al., 2001) and was finally resuspended in 100 μl water. The
concentration of RNA was estimated using a NanoDrop
spectrophotometer (NanoDrop Technologies, Delaware, USA;
courtesy of Prof. D.E. Neal's group at the Hutchison/MRC
Research Centre, Cambridge). The majority of samples yielded
between 20 and 70 ng RNA/mg wet weight, consistent with our
previous experience of human tendon samples, most of which
have low cellularity (Ireland et al., 2001; Jones et al., 2006). Five
of the painful tendinopathy samples and three of the ruptured
tendon samples gave RNA yields between 85 and 330 ng/mg,
significantly above the normal range, consistent with an increase
in cellularity observed in such samples (Åström and Rausing
1995; Jones et al., 2006). The RNAwas diluted to 1 ng/μl, and
stored at −70 °C as aliquots which were thawed once only.
Samples from each group gave well-defined bands of 28S and
18S rRNA on 1.2% (w/v) agarose gels, with no evidence of
significant degradation. ADAMTS-4 mRNA was assayed by
One-Step relative quantitative real-time RT-PCR, normalised to
18S rRNA, as described below.
4.4. Protein extracts and Western blotting
Protein was extracted from tendon tissue samples by homog-
enisation in 3 volumes of extraction buffer (50 mM Tris pH 7.0,
150 mM NaCl, 5 mM EDTA, 0.5% NP-40 (Gao et al., 2002)
with added protease inhibitors: 10 μM E64, 1.5 μM pepstatin Aand 1 mM PMSF) followed by incubation overnight at 4 °C and
centrifugation (14,000 g, 4 °C, 15 min). The protein content of
the clarified extracts was determined, and 50 μg of each extract
was precipitated using trichloroacetic acid (3.3% w/v), washed
with acetone, dried and redissolved in 100 μl of protein gel
sample buffer. Ten μg (20 μl) of extract was boiled with gel
sample buffer for 3 min and subjected to SDS-PAGE under
reducing conditions, using a 4% (w/v) polyacrylamide stacking
gel with a 10% (w/v) polyacrylamide gel. The proteins were
electroblotted onto PVDF membranes, which were then
blocked, incubated with primary antibodies, washed, incubated
with secondary antibodies, washed again, incubated with CDP-
Star (Roche, Lewes, UK) and exposed to film, all using standard
methods. An aliquot of an extract from TGF-β-treated tendon
cells was included on each gel (see Fig. 2, lanes marked cell) to
act as a standard for comparison of the autoradiographs.
4.5. Culture of tendon cells
Tendon cells were isolated by outgrowth from explant cultures
established from mid-tendon samples taken during surgery for
chronic tendinopathy. Cells were maintained and passaged in
DMEM containing 10% (v/v) FCS, penicillin, streptomycin and
25 mMHEPES, and were used between passages 4 and 10. Each
experiment was performed separately using cells derived from at
least three separate patients with similar results. Cells were
seeded at 105/well in 6-well plates and were incubated for 3 days
before the experiment. Theywere rinsedwith serum-free DMEM
containing insulin, transferrin and selenium and were incubated
in the same medium for 48 h. Cytokines and growth factors were
then added to the medium and equivalent additions of vehicle
were made to control wells. After a further incubation (6–48 h),
the cells were rinsed with balanced salts solution and solubilised
in TRI-Reagent (Sigma; 1 ml/well). RNAwas isolated from the
TRI-Reagent extracts by phenol-chloroform phase separation
followed by precipitation with isopropanol and ethanol. Proteins
were extracted from parallel wells using the NP-40-containing
buffer described above, and the extracts were clarified by
centrifugation (14,000 g, 4 °C, 15 min) and prepared for Western
blotting as described above.
Cells for collagen gel cultures were centrifuged (5 min at
300 g), resuspended at 2×106/ml in serum-free DMEM, and
placed on ice. Rat-tail Type I collagen solution (in 0.6% acetic
acid; First-Link, Birmingham, UK) was mixed on ice with
10×DMEM, neutralised using NaOH, and mixed thoroughly
with the cell suspension. Aliquots of the mixture, containing
1×105 cells in 0.5 ml of collagen (1.6 mg/ml) in DMEM, were
placed in the wells of a 24-well plate. The collagen was allowed
to set at room temperature (about 20 min) before being overlaid
with 1 ml of DMEM. Cells for parallel monolayer cultures were
centrifuged, resuspended and plated in neighbouring wells at
2×104 cells/well in DMEM containing 10% FCS to promote
attachment. After attachment, the cells were rinsed and incu-
bated in serum-free DMEM, and monolayer and gel cultures
were incubated for a further 48 h before harvest in TRI-Reagent
(1 ml/well for monolayers and 2ml/well for collagen gels). RNA
was isolated from the TRI-Reagent extracts as described above.
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One-Step real-time RT-PCR reactions were performed in a
GeneAmp 5700 (Applied Biosystems). The primers and probe
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
18S rRNA have been described previously (Ireland et al., 2001;
Corps et al., 2006). Primers and probes for ADAMTS mRNA
were designed using Primer Express (Applied Biosystems). Each
ADAMTS amplicon was chosen to include exon–exon bound-
aries to prevent amplification of genomic DNA, and no signal
was produced if either the RNA or the reverse transcriptase was
omitted. BLASTn searches (www.ncbi.nlm.nih.gov/BLAST)
revealed no significant similarity to other sequences. Each
primer pair generated a single product of the appropriate size, and
no signal was produced when the wrong probe was included with
each primer pair, indicating an absence of cross-reactivity.
Accession numbers, amplicons, forward primer (F), reverse
primer (R) and probe (P) sequences were as follows:
ADAMTS-1 (NM_006988; 77 bp):
F = CCAGTGACCGGGATGCA
R = ACATGTCTGGGACCCACACA
P = TATGACACAGCAATTCTTTTCACCAGACAG-
GAC
ADAMTS-4 (NM_005099; 83 bp):
F = GCAACGTCAAGGCTCCTCTT
R = CTCCACAAATCTACTCAGTGAAGCA
P = AGACCCCGAAGAGCCAAGCGCT
ADAMTS-5 (XM_047802; 73 bp):
F = AGGAGCACTACGATGCAGCTATC
R = CCCAGGGTGTCACATGAATG
P = TGCCCACATAAATCCTCCCGAGTAAACA
Standard curves were run in each assay, using freshly-diluted
aliquots of pooled tendon cell or tissue RNA. For each target, this
produced a linear plot of threshold cycle (Ct) against log(dilution),
whose slope was within 10% of the expected value, indicating a
similar, near-maximum efficiency for each target. This was
confirmed by the demonstration of constant Ct differences with
dilution in pairwise comparisons of each target mRNA. For each
experiment, all samples of RNA were assayed in duplicate or
triplicatewells on the same plate (typically 2 ng/well of total RNA
for mRNA targets, and 20 pg/well of total RNA for the more
abundant 18S rRNA). The values obtained for ADAMTSmRNA
expression were normalised for GAPDH mRNA or 18S rRNA
expression in the same sample, using the formula
ADAMTS= normalising RNAð Þ ¼ 2 Ct normalising RNAð ÞCt ADAMTSð Þ½ 
and correcting for the different input RNA into the 18S rRNA
assay. Values were compared against those for control cultures in
the same experiment (i.e. cultures receiving the same changes ofmedium but incubated with vehicle rather than growth factors or
cytokines) as 100%.
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